BOSTON, May 31, 2018 /PRNewswire/ -- Proteostasis Therapeutics,
Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking
therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that
Po-Shun Lee, M.D., the Company's Chief Medical Officer, will present at the Jefferies 2018 Global Healthcare Conference on
Thursday, June 7, 2018 at 2:30 p.m. ET in New York City.
A live audio webcast of the Jefferies 2018 Global Healthcare Conference presentation will be available on the Investor
Events page in the Investors & Media section of the Company's website, www.proteostasis.com. A replay of the webcast will be available on the
Company's website following the presentation.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to
treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Headquartered in Boston, MA,
the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. In addition to its
multiple programs in cystic fibrosis, Proteostasis Therapeutics has formed a collaboration with Astellas Pharma,
Inc. to research and identify therapies targeting the Unfolded Protein Response (UPR) pathway.
Safe Harbor
To the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the
current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Words such as "aim," "may," "will," "expect," "anticipate," "estimate," "intend," and similar
expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to
identify forward-looking statements. Examples of forward-looking statements made in this release include, without
limitation, statements regarding expected presentation and the timing of the initiation of, patient enrollment in, data from, and
the completion of, our clinical studies and cohorts. Forward-looking statements made in this release involve substantial
risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the
forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be
attained or achieved. Such risks and uncertainties include, without limitation, the possibility final or future results
from our drug candidate trials (including, without limitation, longer duration studies) do not achieve positive results or are
materially and negatively different from or not indicative of the preliminary results reported by the Company (noting that these
results are based on a small number of patients and small data set), uncertainties inherent in the execution and completion of
clinical trials (including, without limitation, the possibility that FDA comments delay, change or do not permit trial
commencement, or intended label, or the FDA requires us to run cohorts sequentially or conduct additional cohorts or
pre-clinical or clinical studies), in the enrollment of CF patients in our clinical trials in a competitive clinical environment,
in the timing of availability of trial data, in the results of the clinical trials, in possible adverse events from our trials,
in the actions of regulatory agencies, in the endorsement, if any, by therapeutic development arms of CF patient advocacy groups
(and the maintenance thereof), and those set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31,
2018 and our other SEC filings. We assume no obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
CONTACTS:
Investors:
David Pitts
Argot Partners
212.600.1902
david@argotpartners.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
View original content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-to-present-at-the-jefferies-2018-global-healthcare-conference-300656917.html
SOURCE Proteostasis Therapeutics, Inc.